Hypermarcas (OTCMKTS:HYPMY) Sets New 12-Month High - Here's What Happened

Key Points

• Intraday 52-week high: Shares hit a new 52-week high of $5.50 but were last traded at $4.09 and are reported down about 5.4% on volume of 5,471 shares.
• Recent results and fundamentals: Hypermarcas has a market cap of $2.55 billion and a PE of 11.85, and it reported quarterly EPS of $0.13 on $414.22 million in revenue with a net margin of 15.71% and ROE of 10.27%.
• Company profile: Hypermarcas is a Brazil-based consumer health and pharmaceutical holding that trades OTC in the U.S. under the ticker HYPMY.

Shares of Hypermarcas (OTCMKTS:HYPMY - Get Free Report) hit a new 52-week high on Tuesday . The stock traded as high as $5.50 and last traded at $4.09, with a volume of 5471 shares traded. The stock had previously closed at $4.2580.

Hypermarcas Stock Down 5.4%

The stock has a market cap of $2.55 billion, a PE ratio of 11.85 and a beta of 0.73. The company has a current ratio of 1.27, a quick ratio of 0.84 and a debt-to-equity ratio of 0.61. The business has a 50-day moving average price of $4.46 and a 200-day moving average price of $4.42.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $414.22 million for the quarter. Hypermarcas had a net margin of 15.71% and a return on equity of 10.27%.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.